title: A double-blind randomized study of clomipramine versus maprotiline in patients with idiopathic pain syndromes.
abstract: Seventy patients with idiopathic syndromes were treated with maprotiline, a noradrenaline reuptake inhibitor, or clomipramine, a serotonin reuptake inhibitor in a 6-week, double-blind, randomized, multicenter trial. Fifty-two patients completed the double-blind phase. Overall, 50% of the patients improved. Significant decreases were seen not only in the levels of pain but also in bodily discomfort, sadness an inner tension (determined by visual analogue scales, VAS). A decrease was also found in the frequency of sleep disturbances, intellectual and emotional inhibition, irritability, guilt feelings, retardation, sadness and suicidal ideas (observed ratings). Sixty-three percent of the subjects showed an overall improvement during treatment with clomipramine as compared to 36% during treatment with maprotiline (p less than 0.05). During clomipramine treatment significant decreases were seen on all the six VAS: sadness, bodily discomfort, inner tension, concentration difficulties, memory disturbances and pain. Bodily discomfort and pain were significantly reduced during maprotiline treatment. The effects produced by clomipramine were also significantly greater than the effects caused by maprotiline as concerns psychic anxiety and inhibition (VAS). The overall reduction in VAS was significantly greater with clomipramine when compared to maprotiline. The most important side effects were dry mouth (both drugs) and sweating (clomipramine). However, in the clomipramine group, 8 patients were excluded due to side effects as compared to 1 patient in the maprotiline group. Thus, the results indicate that antidepressants reduce not only pain but are also of clinical value in the treatment of patients with idiopathic pain syndromes. Drugs with pronounced effects on the serotonin reuptake are to be preferred.
authors.affiliation: Department of Psychiatry, Malmö General Hospital, Sweden.
authors.forename: G
authors.initials: G
authors.lastname: Eberhard
authors.forename: L
authors.initials: L
authors.lastname: von Knorring
authors.forename: H L
authors.initials: HL
authors.lastname: Nilsson
authors.forename: U
authors.initials: U
authors.lastname: Sundequist
authors.forename: G
authors.initials: G
authors.lastname: Björling
authors.forename: H
authors.initials: H
authors.lastname: Linder
authors.forename: K O
authors.initials: KO
authors.lastname: Svärd
authors.forename: L
authors.initials: L
authors.lastname: Tysk
mesh_terms: D000328:Adult; D000368:Aged; D000873:Anthracenes / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D002997:Clomipramine / Q000009:adverse effects / Q000627:therapeutic use*; D003866:Depressive Disorder / Q000188:drug therapy* / Q000523:psychology; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008376:Maprotiline / Q000009:adverse effects / Q000627:therapeutic use*; D008875:Middle Aged; D010146:Pain / Q000188:drug therapy* / Q000523:psychology; D010147:Pain Measurement; D011581:Psychological Tests; D011897:Random Allocation
chemical_list: D000873:Anthracenes; D008376:Maprotiline; D002997:Clomipramine